Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants
Onofrio Laselva, Claire Bartlett, Alec Popa, Hong Ouyang, T. Gunawardena, Tanja Gonska, Theo J. Moraes, Christine E. Bear
Topics & Concepts
PotentiatorIvacaftorHEK 293 cellsMutantCystic fibrosisMedicineCell biologyPharmacologyBiologyCell cultureCystic fibrosis transmembrane conductance regulatorGeneticsGeneInternal medicineCystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchInhalation and Respiratory Drug Delivery